Navigation Links
Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City
Date:3/12/2009

NEW YORK, March 12 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F. Pingpank will present at The Sixth International Symposium on Melanoma, to be held in New York City on March 13-14, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO)

Dr. Pingpank's presentation is titled Targeting the Liver: Percutaneous Hepatic Perfusion/Intra-Arterial. Dr. Pingpank will discuss his experience with The Delcath PHP System(TM) and the Company's Phase III Metastatic Melanoma Study, currently enrolling at eleven leading cancer centers throughout the United States.

The Phase III clinical study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. This clinical study is testing the Delcath PHP System(TM) for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath PHP System(TM) is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while minimizing entry of the drugs into the rest of the patient's circulation. This isolation limits toxicities which result from systemic chemotherapy treatments.

Patients in the Phase III trial are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath PHP System(TM) or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), patients are permitted to "cross-over" from the best alternative care arm to receive treatment with the Delcath System at the time of disease progression.

Commenting on Dr. Pingpank's upcoming presentation, Richard L. Taney, President and CEO of Delcath Systems, stated, "Delcath's pivotal Phase III Metastatic Melanoma Study has experienced significant momentum over the past six months, and this presentation is another important opportunity for Delcath to communicate our experience to the medical and surgical oncology communities. Both Dr. Sanjiv Agarwala, Program Chair of the conference, and Dr. Pingpank, have significant experience with The Delcath PHP System(TM) and, we look forward to future opportunities like these to update the physician and medical communities on the potential of this technology."

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Veteran Rehab Specialist, James Conwell, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania
2. NutraCea Names James C. Lintzenich As Interim CEO
3. Thoratec Presentation at Raymond James Conference to Be Webcast
4. MedCath Corporation to Present at the Raymond James & Associates 30th Annual Institutional Investors Conference
5. PAREXEL International to Present at Raymond James 30th Annual Institutional Investors and the Barclays Capital Global Healthcare Conferences
6. Aflac Incorporated To Present at the Raymond James 30th Annual Institutional Investors Conference
7. LCA-Vision to Present at the Raymond James 30th Annual Institutional Investors Conference
8. CVS Caremark Corporation to Present at the Raymond James Institutional Investors Conference on March 10th
9. Command Medical Products, Inc. Welcomes James Carnall
10. Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board
11. James Roosevelt, Jr. Joins Inverness Medical Innovations Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: